These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 26067321)
1. Role of Angiogenic and Inflammatory Signal Pathways in Psoriasis. Man XY; Zheng M J Investig Dermatol Symp Proc; 2015 Jul; 17(1):43-5. PubMed ID: 26067321 [No Abstract] [Full Text] [Related]
2. Role of Angiogenic Growth Factors in Psoriasis: A Review. Akhtar T; Wani WY; Kamal MA; Kaur R Curr Drug Metab; 2018; 19(11):910-916. PubMed ID: 29663878 [TBL] [Abstract][Full Text] [Related]
3. The role of angiogenesis in the pathogenesis of psoriasis. Chua RA; Arbiser JL Autoimmunity; 2009 Nov; 42(7):574-9. PubMed ID: 19863376 [TBL] [Abstract][Full Text] [Related]
4. Targeting VEGF/VEGFR in the treatment of psoriasis. Li W; Man XY; Chen JQ; Zhou J; Cai SQ; Zheng M Discov Med; 2014 Sep; 18(98):97-104. PubMed ID: 25227750 [TBL] [Abstract][Full Text] [Related]
5. Excessive angiogenesis associated with psoriasis as a cause for cardiovascular ischaemia. Malecic N; Young HS Exp Dermatol; 2017 Apr; 26(4):299-304. PubMed ID: 28156019 [TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214 [TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pasqualetti G; Danesi R; Del Tacca M; Bocci G Pharmacogenomics; 2007 Jan; 8(1):49-66. PubMed ID: 17187509 [TBL] [Abstract][Full Text] [Related]
8. Tracking adult neovascularization during ischemia and inflammation using Vegfr2-LacZ reporter mice. Heidenreich R; Murayama T; Silver M; Essl C; Asahara T; Rocken M; Breier G J Vasc Res; 2008; 45(5):437-44. PubMed ID: 18418002 [TBL] [Abstract][Full Text] [Related]
9. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Scaldaferri F; Vetrano S; Sans M; Arena V; Straface G; Stigliano E; Repici A; Sturm A; Malesci A; Panes J; Yla-Herttuala S; Fiocchi C; Danese S Gastroenterology; 2009 Feb; 136(2):585-95.e5. PubMed ID: 19013462 [TBL] [Abstract][Full Text] [Related]
16. Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model. Ren X; Li J; Zhou X; Luo X; Huang N; Wang Y; Chen X; Wei Y Dermatology; 2009; 219(3):232-8. PubMed ID: 19729876 [TBL] [Abstract][Full Text] [Related]
17. Cutaneous Glucocorticoidogenesis and Cortisol Signaling Are Defective in Psoriasis. Slominski AT; Brożyna AA; Tuckey RC J Invest Dermatol; 2017 Aug; 137(8):1609-1611. PubMed ID: 28735612 [TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules. Zachary I IDrugs; 2003 Mar; 6(3):224-31. PubMed ID: 12789611 [TBL] [Abstract][Full Text] [Related]
19. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116 [TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies? Canavese M; Altruda F; Ruzicka T; Schauber J J Dermatol Sci; 2010 Jun; 58(3):171-6. PubMed ID: 20430590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]